Thrombin Aptamer-Modified Metal-Organic Framework Nanoparticles: Functional Nanostructures for Sensing Thrombin and the Triggered Controlled Release of Anti-Blood Clotting Drugs

Weihai Chen, Ola Karmi, Bilha Willner, Rachel Nechushtai, Itamar WillnerSensors 2019 · OpenReview

TL;DR

Researchers have developed novel metal-organic framework nanoparticles (NMOFs) that act as smart drug delivery systems. These NMOFs are "gated" with DNA and an anti-thrombin aptamer, allowing them to release the anti-clotting drug Apixaban only when thrombin, a key player in blood clotting, is present. This system not only senses thrombin but also provides a more effective and controlled inhibition of blood clot formation compared to free Apixaban.

What Problem Does This Paper Address?

Blood clots, or thrombosis, are a major health concern, leading to conditions like strokes and heart attacks. Current treatments often involve anticoagulants like Apixaban, which inhibit key enzymes in the blood clotting cascade, such as Factor Xa. However, delivering these drugs effectively and controlling their release to minimize side effects and maximize therapeutic benefit remains a challenge. The blood clotting process is a complex cascade, and precisely timing the release of an inhibitor like Apixaban to coincide with the formation of thrombin (which is downstream of Factor Xa) could offer a more nuanced and effective therapeutic strategy. This paper aims to create a system that can sense thrombin and, in response, release an anti-clotting drug, thereby creating a self-regulating system that leverages the natural clotting cascade.

Methods

The core of this work involves the synthesis and functionalization of UiO-68 metal-organic framework nanoparticles (NMOFs).

  • NMOF Synthesis: UiO-68 NMOFs were synthesized using zirconium ions (Zr⁴⁺) and an amino-triphenyldicarboxylic acid ligand.
  • Surface Functionalization: The amine groups on the NMOFs were converted to azide groups (NMOF-N₃). This was followed by a "click chemistry" reaction to attach a dibenzocyclooctyne (DBCO)-modified nucleic acid strand (nucleic acid (1)). This created (1)-modified NMOFs.
  • Drug/Dye Loading: The porous NMOFs were loaded with either the anti-clotting drug Apixaban or rhodamine 6G (as a model dye) by incubation.
  • Gating Mechanism: The loaded NMOFs were then hybridized with a second nucleic acid strand (nucleic acid (2)), which contains an anti-thrombin aptamer sequence. This hybridization formed duplexes that acted as "gates," locking the drug/dye within the NMOFs.
  • Thrombin-Triggered Release: The presence of thrombin was used to trigger the release. Thrombin binds to the anti-thrombin aptamer, causing the duplex gates to separate and release the encapsulated drug or dye.
  • Sensing and Activity Assays: The release of rhodamine 6G was monitored using fluorescence spectroscopy to demonstrate thrombin sensing. Apixaban's anti-clotting activity was evaluated using normal platelet-poor plasma (PPP) assays to measure clot formation time.

Datasets

Not discussed in the paper. The experiments utilize synthesized materials and biological samples (plasma).

Key Insights and Ideas

  • Smart, Self-Regulating Drug Delivery: The NMOFs act as intelligent carriers that can sense a specific biological trigger (thrombin) and respond by releasing a therapeutic agent. This moves beyond simple passive release to an active, responsive system.
  • Leveraging the Clotting Cascade: The system cleverly uses thrombin, a downstream product of the clotting cascade, as the trigger. By releasing Apixaban (a Factor Xa inhibitor), the system can then indirectly influence thrombin production, creating a feedback loop.
  • Enhanced Therapeutic Efficacy: Apixaban-loaded NMOFs demonstrated superior anti-clotting activity compared to free Apixaban, requiring lower doses and leading to significantly longer clot formation times. This suggests a more efficient and sustained therapeutic effect.
  • Selective Unlocking: The system showed high selectivity, with only thrombin effectively unlocking the NMOFs and releasing the drug. Other proteins like BSA, hemoglobin, and VEGF did not trigger release, highlighting the specificity of the aptamer-based gating.
  • Recyclable Nanocarriers: The NMOFs could be reloaded with drugs/dyes and showed similar release profiles in subsequent cycles, indicating their potential for repeated use.

Key Results

  • Thrombin Sensing: The release of rhodamine 6G from the NMOFs was directly proportional to the concentration of thrombin, demonstrating a clear sensing capability.
  • Apixaban Release Kinetics: The release of Apixaban was also thrombin-concentration dependent, with saturation achieved at approximately 4 µM thrombin. The release process typically leveled off after about 180 minutes.
  • Improved Anti-Clotting Activity:
    • At a drug concentration of 3.2 nM, free Apixaban resulted in clot formation in ~40 minutes, while Apixaban-loaded NMOFs extended this to ~90 minutes.
  • At 5.4 nM, free Apixaban took ~45 minutes, whereas the NMOFs achieved clot formation in ~120 minutes.
  • Crucially, the NMOFs at 3.2 nM Apixaban showed a longer clot formation time (90 min) than free Apixaban at a higher concentration of 5.4 nM (45 min), indicating a significant dose-sparing effect.
  • NMOF Loading Capacity: The NMOFs were found to have a loading capacity of approximately 9.4 nmol/mg for nucleic acid (1) and 32.5 nmol/mg for Apixaban.
  • Structural Integrity: TEM and SEM images confirmed that the NMOFs maintained their structural integrity after drug release and could be reloaded.

Limitations and Future Work

  • In Vitro vs. In Vivo: The study was conducted using in vitro assays. Further investigation is needed to assess the efficacy and safety of these NMOFs in in vivo models of thrombosis.
  • Drug Specificity: While the study focused on Apixaban, the concept of thrombin-gated release could be extended to other anti-clotting drugs. However, the specific interaction and efficacy of these drugs when released from NMOFs would need to be evaluated.
  • Long-Term Stability and Biodegradation: The long-term stability of the NMOFs in biological environments and their biodegradation pathways are not extensively discussed.
  • Comparison to Other Assays: The authors note the importance of comparing their system to other assays probing Apixaban-induced inhibition, particularly light-scattering assays, and suggest this would be valuable.
  • Autonomous Control: The paper highlights the "autonomous dose-controlled release" and the potential for a feedback mechanism where drug release inhibits thrombin formation, which in turn slows drug release. Further exploration of this complex interplay in a physiological context would be beneficial.

Summary updated

Abstract

This paper features the synthesis of thrombin-responsive, nucleic acid-gated, UiO-68 metal–organic framework nanoparticles (NMOFs) loaded with the drug Apixaban or rhodamine 6G as a drug model. Apixaban acts as an inhibitor of blood clots formation. The loads in the NMOFs are locked by duplex nucleic acids that are composed of anchor nucleic acids linked to the NMOFs that are hybridized with the anti-thrombin aptamer. In the presence of thrombin, the duplex gating units are separated through the formation of thrombin–aptamer complexes. The unlocking of the NMOFs releases the drug (or the drug model). The release of the drug is controlled by the concentration of thrombin. The Apixaban-loaded NMOFs revealed improved inhibition, as compared to free Apixaban, toward blood clot formation. This is reflected by their longer time intervals for inducing clot formation and the decreased doses of the drug required to affect clots formation. The beneficial effects of the Apixaban-loaded NMOFs are attributed to the slow-release mechanism induced by the NMOFs carriers, where the inhibition of factor Xa in the blood clotting cycle retards the formation of thrombin, which slows down the release of the drug.
BibTeX
@inproceedings{chen2019thrombin,
  author = {Weihai Chen and Ola Karmi and Bilha Willner and Rachel Nechushtai and Itamar Willner},
  title = {{Thrombin Aptamer-Modified Metal-Organic Framework Nanoparticles: Functional Nanostructures for Sensing Thrombin and the Triggered Controlled Release of Anti-Blood Clotting Drugs}},
  booktitle = {Sensors},
  year = {2019},
  url = {https://openreview.net/forum?id=mI9bfr9YDls},
}
Figure